Equities Analysts Offer Predictions for PLRX FY2029 Earnings

Pliant Therapeutics, Inc. (NASDAQ:PLRX - Free Report) - Investment analysts at HC Wainwright boosted their FY2029 earnings per share (EPS) estimates for Pliant Therapeutics in a research note issued on Tuesday, March 4th. HC Wainwright analyst E. Arce now expects that the company will earn $1.80 per share for the year, up from their previous forecast of $1.75. HC Wainwright currently has a "Neutral" rating on the stock. The consensus estimate for Pliant Therapeutics' current full-year earnings is ($3.64) per share.

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($0.99) by $0.17.

PLRX has been the subject of several other reports. Needham & Company LLC reiterated a "hold" rating and issued a $10.00 target price on shares of Pliant Therapeutics in a report on Tuesday, March 4th. Cantor Fitzgerald reiterated a "neutral" rating on shares of Pliant Therapeutics in a research report on Tuesday, March 4th. Canaccord Genuity Group reissued a "hold" rating and set a $4.00 target price (down from $43.00) on shares of Pliant Therapeutics in a research note on Monday, February 10th. Oppenheimer reaffirmed a "market perform" rating on shares of Pliant Therapeutics in a research report on Monday, February 10th. Finally, Leerink Partnrs lowered Pliant Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, March 3rd. Twelve investment analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $13.31.

Remove Ads

Pliant Therapeutics Trading Down 11.7 %

Shares of NASDAQ:PLRX traded down $0.19 during midday trading on Thursday, reaching $1.43. The company had a trading volume of 2,090,416 shares, compared to its average volume of 856,056. The company has a fifty day simple moving average of $8.11 and a two-hundred day simple moving average of $11.47. The firm has a market cap of $87.57 million, a price-to-earnings ratio of -0.43 and a beta of 1.18. Pliant Therapeutics has a 1-year low of $1.26 and a 1-year high of $16.52. The company has a debt-to-equity ratio of 0.09, a quick ratio of 10.26 and a current ratio of 10.26.

Insider Transactions at Pliant Therapeutics

In related news, CEO Bernard Coulie sold 52,419 shares of Pliant Therapeutics stock in a transaction on Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $587,092.80. Following the completion of the sale, the chief executive officer now owns 430,517 shares of the company's stock, valued at approximately $4,821,790.40. The trade was a 10.85 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, General Counsel Mike Ouimette sold 13,270 shares of the stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $148,624.00. Following the transaction, the general counsel now directly owns 80,774 shares in the company, valued at approximately $904,668.80. This represents a 14.11 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,855 shares of company stock valued at $1,026,628 in the last three months. Corporate insiders own 6.40% of the company's stock.

Hedge Funds Weigh In On Pliant Therapeutics

A number of institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its holdings in Pliant Therapeutics by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 12,903 shares of the company's stock worth $170,000 after acquiring an additional 1,209 shares during the period. Swiss National Bank increased its stake in shares of Pliant Therapeutics by 1.6% in the fourth quarter. Swiss National Bank now owns 95,700 shares of the company's stock worth $1,260,000 after purchasing an additional 1,500 shares during the period. Atria Investments Inc lifted its position in shares of Pliant Therapeutics by 18.1% during the 4th quarter. Atria Investments Inc now owns 11,821 shares of the company's stock worth $156,000 after purchasing an additional 1,812 shares during the last quarter. R Squared Ltd bought a new stake in Pliant Therapeutics during the 4th quarter valued at approximately $33,000. Finally, Charles Schwab Investment Management Inc. grew its holdings in Pliant Therapeutics by 0.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 459,384 shares of the company's stock valued at $6,050,000 after buying an additional 2,721 shares during the last quarter. Institutional investors own 97.30% of the company's stock.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.